MTIM
CARM

Marathon Trading Investment Management’s Carisma Therapeutics CARM Stock Holding History

Marathon Trading Investment Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-760
Closed -$70K – 390
2021
Q2 		$70K Sell
760
-250
-25% -$15.9K 0.01% 282
2021
Q1 		$53K Hold
1,010
– – ﹤0.01% 380
2020
Q4 		$27K Hold
1,010
– – ﹤0.01% 339
2020
Q3 		$28K Buy
+1,010
New +$20.2K ﹤0.01% 254
2020
Q1 		– Sell
-655
Closed -$10.7K – 155
2019
Q4 		$14K Sell
655
-1,845
-74% -$42.4K ﹤0.01% 187
2019
Q3 		$59K Buy
+2,500
New +$58.5K 0.01% 180

Other funds holding CARM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Marathon Trading Investment Management's CARM Position: Q3 2021 in Review

Marathon Trading Investment Management sold out of Carisma Therapeutics (CARM) in Q3 2021, closing a stake of 760 shares — an estimated $70K sold.

Marathon Trading Investment Management first reported a position in CARM in Q3 2019 and held it in 6 quarters. The position peaked at $70K in Q2 2021. 103 funds tracked by Wall St. Rank hold CARM as of Q3 2021.

  • Marathon Trading Investment Management reported no remaining Carisma Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Marathon Trading Investment Management sold 760 Carisma Therapeutics shares in Q3 2021, an estimated $70K.
  • Marathon Trading Investment Management first reported a position in Carisma Therapeutics in Q3 2019 and held it in 6 quarters.
  • Marathon Trading Investment Management's Carisma Therapeutics position peaked at $70K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2021.

Based on Marathon Trading Investment Management's 13F filing for Q3 2021, filed 12 Nov 2021.